Today, Evaxion reported the full EVX-01 dosing of the first patient in the phase II study of EVX-01.
Q1e sales SEK 43m, down 2% y-o-y, adj. EBIT SEK 0m (0m) Tough comps due to Duni product-launch inven...
Redeye in this research piece comments Acconeer's big design win of SEK 330m.
Redeye briefly comments on Circio’s rights issue. We pause our coverage.
Q1 report due 7 May Q1'24e net sales SEK 206m, EBITA SEK 30m We reiterate our fair value range of SE...
Redeye reinforces its view of Vertiseit following a solid Q1 report, with slightly higher ARR growth...
Redeye hosts Circio's webcast in which CEO, Dr Erik Digman Wiklund, provides an overview of the late...
Redeye comments on Medrave's new contract with VGR.
Fiskars' main markets have likely remained subdued during Q1.
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibit...
DT reports Q1 results on Apr 25. Q1 may have been a bit muted, but growth is likely to pick up pace ...
Inför Q1-rapporten räknar Analysguiden med en lägre omsättning, drivet av konjunkturen och avyttring...
Redeye comments on Truecaller ahead of its Q1 results (due 7 May).
Atria is currently ramping up its EUR 160m poultry investment in Finland.
Redeye comments on the positive results from a proof-of-concept study with the veterinary candidate ...
Redeye returns with an update following Annexin’s Q1 report, which offered no surprises.
Q1e: Clean EBIT of ~SEK 37m Pulp prices move higher, demand stronger Fair value range: SEK 9-16/sh ...
The main focus on the report will be on the progress regarding the start of production for Hella and...
Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured ad...
The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the e...
